DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has established a European business unit to address EU development and commercialization needs for its novel technologies, including Lymphoseek® (99mTc-tilmanocept).
